The strong allogeneic response to donor MHC molecules in transplantation and the weak response to tumor antigens ... HLA class II alleles into the patient's own dendritic cells (Fig.

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

A new editorial titled "Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity" has been published in Oncotarget. Two studies using CRISPR screens in cancer cells ...

Therapeutics reports preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, ...

In case of success, the company counts on a $1-$5 billion market to open ... cell line derived from a breast cancer cell. It expresses HLA class I and II molecules, which may make patients with ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.

A2 Bio shares enrollment updates on EVEREST-1 and EVEREST ... a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and ...

The BASECAMP-1 abstract (number 589: "BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and ... confer selective tumor killing. Normal cells are protected ...

HOUSTON, November 09, 2024--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class ... 1 abstract (number 589: "BASECAMP-1 is an efficient ...